Endocrine Therapies in Breast Cancer
Series: Oxford Oncology Library;
- Publisher's listprice GBP 32.99
-
14 894 Ft (14 185 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 10% (cc. 1 489 Ft off)
- Discounted price 13 405 Ft (12 767 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
14 894 Ft
Availability
printed on demand
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Publisher OUP Oxford
- Date of Publication 8 November 2007
- ISBN 9780199218141
- Binding Paperback
- No. of pages130 pages
- Size 179x99x6 mm
- Weight 112 g
- Language English
- Illustrations 10 black and white illustrations 0
Categories
Short description:
Breast cancer is one of the leading causes of cancer mortality in women worldwide. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to managing their disease. This pocketbook summarises the latest evidence-based information on the use of endocrine therapies in the management of breast cancer.
MoreLong description:
Breast cancer is one of the leading causes of cancer mortality in women worldwide, and the risk of disease recurrence continues despite improvements in screening and treatment. For patients with hormone receptor-positive breast cancer, some form of endocrine therapy is central to the management of their disease. Tamoxifen has long been the mainstay of endocrine therapy in this group of patients. However, there is mounting evidence showing that the aromatase inhibitors are able to reduce overall oestrogen levels and appear to be better tolerated over a long term than tamoxifen. New and emerging indications for the aromatase inhibitors are providing clinicans (and patients) with alternative treatment options with differing side effect profiles.
Part of the Oxford Oncology Library, this pocketbook will summarise the latest evidence-based and practical information on the use of endrocrine therapies in the management of breast cancer (early stage, metastatic disease, and prevention of disease). With contributions from leading oncologists from the MD Anderson Cancer Center, the book covers the range of endocrine therapies currently available to clinicians including ovarian ablation, anti-estrogens, aromatase inhibitors, fulvestrant, progestins, androgens, and combination endocrine and chemotherapy. The book also includes useful chapters on the identification and optimal selection of patients for endocrine therapy as well as the role of endocrine treatments in the prevention of breast cancer.
This book will serve as an invaluable reference for all health care professionals involved in the management of patients with breast cancer.
...an excellent concise reference for physicians involved in the care of breast cancer patients.
Table of Contents:
Selection of patients for endocrine therapies
Ovarian ablation
Antiestrogens
Aromatase inhibitors in early and advanced disease
Fulvestrant - Metastatic disease
Progestins and androgens
Combined endocrine and chemotherapy
Hormonal replacement therapy in patients with prior history of breast cancer
Prevention
